WA-KYMETA
18.3.2024 13:01:27 CET | Business Wire | Press release
World-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com), announced today at SATELLITE 2024 that the Osprey u8 HGL, a hybrid geostationary/low Earth orbit (GEO/LEO/LTE) terminal purpose-built for military users, is shipping out of their facility in Woodinville, Washington. This marks the first commercially available multi-orbit terminal and the first multi-orbit terminal on Eutelsat OneWeb’s LEO network. Kymeta announced the official launch in October last year and is fulfilling a backlog of orders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318848741/en/
Kymeta - The Future of Military SATCOM is now. On the move GEO-LEO-LTE from one single terminal - Osprey u8 HGL (Graphic: Business Wire)
In February, the Kymeta team demonstrated in the field the capabilities of the new Osprey u8 HGL delivering resilient, auto-PACE ready communications for the armed forces to meet the demands of challenging and rugged military environments. The multi-orbit, multi-network capabilities of the Osprey u8 HGL terminal will offer even greater availability, while being durable, low power consuming, having low visibility, and easy to use.
The Osprey u8 HGL includes a field swappable modem cartridge and a OneWeb modem to enable connectivity with the Eutelsat OneWeb LEO network. At launch an iDirect 950mp cartridge is available enabling TRANSEC services over GEO. Other cartridge configurations will be available soon enabling end users to customize their terminal configuration based on their mission needs.
Initial feedback was overwhelmingly positive, with one military member stating: “This is everything we’ve been looking for in a terminal, form function and features. The LEO to GEO switching far exceeded our expectations. It’s amazing that Kymeta is already delivering on the community’s urgent need for multi-orbit SATCOM.”
Others in attendance at Army field demonstrations commented, “I cannot wait to get started with these!” and “Wow! It tracks satellites over some very difficult terrain.”
“The Kymeta Osprey HGL has a unique capability to address government requirements in support of government PACE plans,” said Ian Canning, Chief Operating Officer, OneWeb Technologies. “The Osprey supports multi-network/orbit requirements through the concurrent LTE/satellite configuration with the added benefit of now being able to add OneWeb LEO capabilities.”
Jon Osler, Senior Vice President Global Sales and Services of Kymeta, commented: “In the contemporary military landscape, mobile connectivity has become indispensable for achieving success. Unlike any other sector, the military relies heavily on dependable, adaptable, and resilient on-the-go communication systems to fulfill its operational and training needs. We take pride in our longstanding partnership with the military, delivering cutting-edge solutions that meet and exceed expectations.”
This milestone further establishes Kymeta as the leader in the multi-X revolution. Attendees of SATELLITE 2024 in Washington, DC, March 18– 20 are encouraged to visit Kymeta’s meeting room 156 to see the Osprey u8 HGL in person and to speak with a member of the Kymeta team.
About Kymeta
Kymeta is the industry leader in flat panel satellite antennas, providing purpose-built solutions across a variety of enterprise and military applications and unlocking the commercial value of space to address the vast, unmet demand for ubiquitous broadband and truly mobile connectivity for customers around the world. Its innovative metasurface technology, coupled with a software-first approach, delivers the first commercially available, metamaterial-based and electronically steered flat panel satellite antenna. Kymeta’s low-cost, low power and high throughput solutions make it easy to connect on the move or while stationary – for any vehicle, vessel, aircraft, or fixed platform – enabling industries on earth to transform their operations by harnessing capacity in space.
Kymeta is a privately held company based in Redmond, Washington.
For more information, visit kymetacorp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318848741/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom